United Therapeutics Corporation — FY2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone quarterly filing; Q4 figures are included below where available. United Therapeutics develops and sells therapies primarily for pulmonary arterial hypertension (PAH), alongside an oncology product and research into organ transplantation technologies.
Financial performance and liquidity
| Metric | FY2018 | FY2017 | Change |
|---|---|---|---|
| Revenue | $1,627.8 million | $1,725.3 million | Down 5.7% |
| Gross profit | $1,429.1 million | $1,619.6 million | Down 11.8% |
| Operating income | $805.4 million | $814.9 million | Down 1.2% |
| Net income | $589.2 million | $417.9 million | Up 41.0% |
| Diluted EPS | $13.39 | $9.31 | Up 43.9% |
| Operating cash flow | $778.4 million | $474.2 million | Up 64.2% |
Gross margin was approximately 87.8% versus 93.9% in 2017; operating margin was approximately 49.5% versus 47.2%, and net margin approximately 36.2% versus 24.2%. The gross-margin decline largely reflects higher Adcirca royalties and milestone costs. Net income increased despite lower revenue, aided by a lower tax provision and a $93.4 million share-based compensation benefit tied primarily to the decline in the stock price; those awards can make reported earnings volatile.
Cash, cash equivalents, and marketable investments totaled $1,858.5 million at year-end, up 30.0%. Total assets were $3,401.0 million and stockholders’ equity $2,788.6 million. Year-end revolving credit debt was $250.0 million. The company subsequently borrowed $800.0 million in January 2019 to fund the Arena ralinepag license payment, bringing debt outstanding to $1,050.0 million as of February 27, 2019. The facility matures in 2023 and is subject to covenants; the company reported compliance at year-end.
Capital spending was $184.4 million. Investing cash outflow was $820.6 million, principally reflecting investment purchases, capital expenditures, and the SteadyMed acquisition. The company reported current assets of $1,768.0 million and current liabilities of $276.6 million.
Revenue by product and Q4 results
| Product | FY2018 sales | FY2017 sales | Year-over-year change |
|---|---|---|---|
| Remodulin | $599.0 million | $670.9 million | Down 10.7% |
| Tyvaso | $415.2 million | $372.9 million | Up 11.3% |
| Adcirca | $323.7 million | $419.7 million | Down 22.9% |
| Orenitram | $205.1 million | $185.8 million | Up 10.4% |
| Unituxin | $84.8 million | $76.0 million | Up 11.6% |
Adcirca’s decline followed generic entry in August 2018. Remodulin sales fell partly because 2017 included a one-time $47.4 million international distributor inventory purchase and subsequent changes in distributor responsibilities and pricing. Tyvaso, Orenitram, and Unituxin grew, supported by patient growth and/or pricing. Q4 2018 revenue was $381.4 million and net income was $65.3 million, compared with $464.7 million and $19.0 million, respectively, in Q4 2017. Quarterly earnings included substantial share-based compensation fluctuations.
Material changes, outlook, risks, and unusual items
- Outlook: Management expects 2019 revenue to decline versus 2018, principally because generic Adcirca will compete for a full year and generic Remodulin may enter the U.S. and additional international markets. Management sees potential for a return to revenue growth as early as 2020, conditional on pipeline, regulatory, launch, demand, pricing, and reimbursement outcomes. No specific revenue or earnings guidance was provided.
- Generic exposure: Generic Adcirca materially reduced demand; average monthly bottles sold from launch through December 2018 were down more than 55% versus the pre-launch 2018 average. The Adcirca returns allowance rose to $22.4 million from $7.2 million. U.S. generic Remodulin launches were anticipated during 2019; international generic competition also poses risk. Settlements permit potential generic Tyvaso entry from 2026 and Orenitram from 2027, subject to earlier-entry provisions.
- Pipeline and commercial execution: The FDA approved the Implantable System for Remodulin in July 2018, but Medtronic must meet remaining FDA conditions before launch. Management anticipated a staged U.S. launch in 2019, dependent on Medtronic. The FREEDOM-EV Orenitram study met its primary endpoint, and an NDA supplement was submitted in December 2018. Other key programs include the BEAT, INCREASE, PERFECT, DISTINCT, and ralinepag studies; clinical results and approvals are uncertain.
- Large transaction and leverage: The January 2019 Arena license closed after year-end with an $800.0 million upfront payment, funded by borrowing, and was to be expensed as R&D in Q1 2019. Additional contingent approval payments include $250 million for a qualifying U.S. inhaled ralinepag approval and $150 million for qualifying approvals in specified countries, plus royalties. The filing also describes up to $340 million in SM04646 development milestones, up to $50 million for Treprostinil Technosphere milestones, and a possible $75 million Trevyent milestone payment.
- Unusual expenses and accounting: The company recorded $53.5 million of impairments on private-company investments in 2018, following $49.6 million in 2017. R&D expense rose 35.3% to $357.9 million, reflecting pipeline expansion and license payments. Cost of product sales rose 88.0% to $198.7 million, primarily due to higher Adcirca royalty expense; the effective royalty and milestone burden was approximately 42.5% of Adcirca sales. The 2017 period included a $210 million DOJ settlement accrual and payment, while 2018 benefited from the lower tax rate under U.S. tax reform.
- Compliance and operational risks: A five-year Corporate Integrity Agreement, entered into in connection with the 2017 DOJ settlement concerning patient-assistance support, runs through December 2022. Risks also include payer pricing and reimbursement pressure, product safety, manufacturing and sole-source supply reliance, patent challenges, and clinical or regulatory setbacks. MannKind disclosed substantial doubt about its ability to continue as a going concern, which could affect the Treprostinil Technosphere program.
Most important facts for investors to verify
- Whether 2019 generic entry for Remodulin occurs as anticipated, and the pace and financial impact of Adcirca generic erosion and related product returns.
- Actual 2019 revenue, margin, and cash-flow performance against management’s expectation of lower revenue; distinguish recurring performance from tax and share-based compensation effects.
- Post-Arena financing: debt balance, interest expense, covenant headroom, and the capacity to fund the $800 million payment and continuing pipeline investment.
- Regulatory and commercial milestones for the implantable Remodulin system, Trevyent, and major clinical programs, including FREEDOM-EV label action and planned study readouts.
- Whether the $22.4 million Adcirca returns allowance adequately reflects downstream inventory exposure, and whether further reserve adjustments are needed.
- Progress under the Corporate Integrity Agreement and any material legal, regulatory, manufacturing, or third-party supplier developments.
The filing reports unqualified audit opinions on the financial statements and internal control over financial reporting; SteadyMed was excluded from the year-end internal-control assessment under the permitted acquisition-year guidance.